Healthcare provider profile · identity verified

Horacio Capote, M.D.

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · AMHERST, NY · NPI 1053475939

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Horacio Capote, M.D. received $235,000.19 in general payments during 2025 across 365 reported records.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 44.8% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 23 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Aristada, Caplyta, Fanapt, Invega Sustenna, Rexulti, Trintellix, Vraylar.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Vraylar by this doctor in 2024.

Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARISTADA as an associated drug or biological on 76041 records involving 17486 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Aristada by this doctor in 2024.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Caplyta by this doctor in 2024.

Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Caplyta as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Caplyta by this doctor in 2024.

Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Invega Sustenna by this doctor in 2024.

Janssen Scientific Affairs, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 488 records involving 397 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Invega Sustenna by this doctor in 2024.

Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Abilify Maintena by this doctor in 2024.

Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Rexulti by this doctor in 2024.

Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Abilify Maintena by this doctor in 2024.

Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Nuedexta by this doctor in 2024.

Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Rexulti by this doctor in 2024.

Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 87 records involving 83 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Abilify Maintena by this doctor in 2024.

Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Rexulti by this doctor in 2024.

Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Trintellix by this doctor in 2024.

Vanda Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FANAPT as an associated drug or biological on 95605 records involving 21383 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Fanapt by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$235,000.19

365 reported records · 23 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	Unresolved — no canonical attribution shown	$105,228.00	44.8%	114	2025
Otsuka America Pharmaceutical, Inc.	Unresolved — no canonical attribution shown	$68,270.86	29.1%	92	2025
Janssen Pharmaceuticals, Inc	Unresolved — no canonical attribution shown	$31,697.64	13.5%	49	2025
Teva Pharmaceuticals USA, Inc.	Unresolved — no canonical attribution shown	$11,423.82	4.9%	25	2025
ABBVIE INC.	Unresolved — no canonical attribution shown	$5,619.80	2.4%	17	2025
Axsome Therapeutics, Inc.	Unresolved — no canonical attribution shown	$5,444.33	2.3%	4	2025
Indivior Inc.	Unresolved — no canonical attribution shown	$3,288.80	1.4%	4	2025
Eli Lilly and Company	Unresolved — no canonical attribution shown	$2,625.00	1.1%	3	2025
Neurocrine BioSciences, Inc.	Unresolved — no canonical attribution shown	$388.51	0.2%	13	2025
E.R. Squibb & Sons, L.L.C.	Unresolved — no canonical attribution shown	$228.07	0.1%	6	2025
Vanda Pharmaceuticals Inc.	Unresolved — no canonical attribution shown	$136.65	0.1%	6	2025
Lundbeck LLC	Unresolved — no canonical attribution shown	$135.07	0.1%	11	2025
Alkermes, Inc.	Unresolved — no canonical attribution shown	$131.05	0.1%	6	2025
Otsuka Pharmaceutical Development & Commercialization, Inc.	Unresolved — no canonical attribution shown	$79.40	0.0%	1	2025
Takeda Pharmaceuticals U.S.A., Inc.	Unresolved — no canonical attribution shown	$71.12	0.0%	4	2025
JAZZ PHARMACEUTICALS INC.	Unresolved — no canonical attribution shown	$42.95	0.0%	1	2025
Boehringer Ingelheim Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$38.85	0.0%	2	2025
Supernus Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$30.23	0.0%	2	2025
Eisai Inc.	Unresolved — no canonical attribution shown	$29.10	0.0%	1	2025
Janssen Scientific Affairs, LLC	Unresolved — no canonical attribution shown	$27.96	0.0%	1	2025
Bausch Health US, LLC	Unresolved — no canonical attribution shown	$21.72	0.0%	1	2025
PFIZER INC.	Unresolved — no canonical attribution shown	$21.03	0.0%	1	2025
LivaNova USA, Inc.	Unresolved — no canonical attribution shown	$20.23	0.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program	$168,920.50	43
Travel and Lodging	$28,799.42	101
Consulting Fee	$24,319.00	11
Food and Beverage	$7,518.32	208
Honoraria	$5,400.00	1
Education	$42.95	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
CAPLYTA Normalized: caplyta	Drug	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	$105,228.00	114	2025
Source payment records 2025-01-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $20.17 · Open Payments source 2025-01-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $113.67 · Open Payments source 2025-01-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,700.00 · Open Payments source 2025-01-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.40 · Open Payments source 2025-02-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.49 · Open Payments source 2025-05-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $30.54 · Open Payments source 2025-05-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $456.88 · Open Payments source 2025-05-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $842.74 · Open Payments source 2025-05-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $458.20 · Open Payments source 2025-05-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $121.85 · Open Payments source 2025-05-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $20.73 · Open Payments source 2025-06-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $20.88 · Open Payments source 2025-07-01 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1.79 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $5,550.00 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.81 · Open Payments source 2025-07-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $124.89 · Open Payments source 2025-07-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,775.00 · Open Payments source 2025-08-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $25.18 · Open Payments source 2025-08-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1.12 · Open Payments source 2025-08-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $13.44 · Open Payments source 2025-08-21 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1.21 · Open Payments source 2025-08-21 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.38 · Open Payments source 2025-08-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $31.49 · Open Payments source 2025-08-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $133.49 · Open Payments source 2025-08-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $113.48 · Open Payments source 2025-08-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $221.47 · Open Payments source 2025-08-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $120.29 · Open Payments source 2025-09-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,885.00 · Open Payments source 2025-09-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $5,550.00 · Open Payments source 2025-09-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $216.96 · Open Payments source 2025-09-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $306.68 · Open Payments source 2025-09-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $182.25 · Open Payments source 2025-09-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $124.99 · Open Payments source 2025-09-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $5,550.00 · Open Payments source 2025-09-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $316.97 · Open Payments source 2025-09-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.98 · Open Payments source 2025-09-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $32.62 · Open Payments source 2025-09-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $212.77 · Open Payments source 2025-09-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $5.60 · Open Payments source 2025-09-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $32.62 · Open Payments source 2025-09-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.75 · Open Payments source 2025-09-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $31.95 · Open Payments source 2025-09-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4.00 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $503.97 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $65.70 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $235.00 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $306.75 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $144.19 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $33.76 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $33.76 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $56.87 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $49.33 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $34.57 · Open Payments source 2025-10-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $247.88 · Open Payments source 2025-10-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $395.97 · Open Payments source 2025-10-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $247.88 · Open Payments source 2025-10-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $103.26 · Open Payments source 2025-10-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $129.40 · Open Payments source 2025-10-21 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $206.16 · Open Payments source 2025-10-21 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $316.96 · Open Payments source 2025-10-21 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $125.00 · Open Payments source 2025-10-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $124.74 · Open Payments source 2025-11-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,775.00 · Open Payments source 2025-11-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $5,550.00 · Open Payments source 2025-11-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $5,550.00 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $119.19 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $188.48 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $348.73 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $706.04 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $203.48 · Open Payments source 2025-11-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,440.00 · Open Payments source 2025-11-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $109.11 · Open Payments source 2025-11-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $5.45 · Open Payments source 2025-11-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $32.62 · Open Payments source 2025-11-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $207.95 · Open Payments source 2025-11-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3.12 · Open Payments source 2025-11-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $169.40 · Open Payments source 2025-11-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,131.36 · Open Payments source 2025-11-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.07 · Open Payments source 2025-11-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,022.89 · Open Payments source 2025-11-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $125.35 · Open Payments source 2025-11-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $238.70 · Open Payments source 2025-11-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $113.48 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $10.50 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $6,660.00 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,440.00 · Open Payments source 2025-12-01 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.14 · Open Payments source 2025-12-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $124.99 · Open Payments source 2025-12-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $185.95 · Open Payments source 2025-12-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $792.97 · Open Payments source 2025-12-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $25.52 · Open Payments source 2025-12-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $30.14 · Open Payments source 2025-12-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $121.65 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $32.62 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $10.21 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $6.17 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $108.65 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $762.98 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $339.60 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $389.10 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,220.00 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,885.00 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,885.00 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,775.00 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,440.00 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $5,550.00 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $5,550.00 · Open Payments source 2025-12-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $23.20 · Open Payments source 2025-12-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $9.17 · Open Payments source 2025-12-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $129.98 · Open Payments source 2025-12-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $209.12 · Open Payments source 2025-12-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $45.00 · Open Payments source 2025-12-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $10.04 · Open Payments source 2025-12-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $5,550.00 · Open Payments source
REXULTI Normalized: rexulti	Drug	Lundbeck LLC, Otsuka America Pharmaceutical, Inc.	$68,387.83	102	2025
Source payment records 2025-01-08 · Otsuka America Pharmaceutical, Inc. · $19.97 · Open Payments source 2025-01-09 · Otsuka America Pharmaceutical, Inc. · $31.54 · Open Payments source 2025-01-09 · Otsuka America Pharmaceutical, Inc. · $17.07 · Open Payments source 2025-01-09 · Otsuka America Pharmaceutical, Inc. · $8.13 · Open Payments source 2025-01-09 · Otsuka America Pharmaceutical, Inc. · $31.54 · Open Payments source 2025-01-09 · Otsuka America Pharmaceutical, Inc. · $31.54 · Open Payments source 2025-01-09 · Otsuka America Pharmaceutical, Inc. · $18.00 · Open Payments source 2025-01-13 · Otsuka America Pharmaceutical, Inc. · $12.99 · Open Payments source 2025-01-17 · Lundbeck LLC · $9.77 · Open Payments source 2025-01-22 · Otsuka America Pharmaceutical, Inc. · $24.63 · Open Payments source 2025-01-25 · Otsuka America Pharmaceutical, Inc. · $2,808.00 · Open Payments source 2025-01-27 · Lundbeck LLC · $16.00 · Open Payments source 2025-01-29 · Otsuka America Pharmaceutical, Inc. · $3.50 · Open Payments source 2025-01-29 · Otsuka America Pharmaceutical, Inc. · $14.70 · Open Payments source 2025-02-12 · Otsuka America Pharmaceutical, Inc. · $14.05 · Open Payments source 2025-02-12 · Otsuka America Pharmaceutical, Inc. · $12.64 · Open Payments source 2025-02-12 · Lundbeck LLC · $16.84 · Open Payments source 2025-02-13 · Lundbeck LLC · $15.31 · Open Payments source 2025-04-18 · Otsuka America Pharmaceutical, Inc. · $351.00 · Open Payments source 2025-05-12 · Otsuka America Pharmaceutical, Inc. · $20.44 · Open Payments source 2025-05-21 · Lundbeck LLC · $15.89 · Open Payments source 2025-06-04 · Otsuka America Pharmaceutical, Inc. · $14.61 · Open Payments source 2025-06-04 · Otsuka America Pharmaceutical, Inc. · $10.81 · Open Payments source 2025-06-12 · Otsuka America Pharmaceutical, Inc. · $392.96 · Open Payments source 2025-06-12 · Lundbeck LLC · $14.81 · Open Payments source 2025-06-13 · Lundbeck LLC · $1.55 · Open Payments source 2025-06-14 · Otsuka America Pharmaceutical, Inc. · $468.44 · Open Payments source 2025-06-23 · Otsuka America Pharmaceutical, Inc. · $18.79 · Open Payments source 2025-06-24 · Lundbeck LLC · $11.13 · Open Payments source 2025-06-25 · Otsuka America Pharmaceutical, Inc. · $877.50 · Open Payments source 2025-07-01 · Otsuka America Pharmaceutical, Inc. · $13.36 · Open Payments source 2025-07-07 · Otsuka America Pharmaceutical, Inc. · $4,104.00 · Open Payments source 2025-07-10 · Lundbeck LLC · $10.90 · Open Payments source 2025-07-14 · Otsuka America Pharmaceutical, Inc. · $9.52 · Open Payments source 2025-07-15 · Otsuka America Pharmaceutical, Inc. · $17.80 · Open Payments source 2025-07-31 · Otsuka America Pharmaceutical, Inc. · $11.23 · Open Payments source 2025-08-04 · Otsuka America Pharmaceutical, Inc. · $12.57 · Open Payments source 2025-08-22 · Otsuka America Pharmaceutical, Inc. · $2,808.00 · Open Payments source 2025-09-10 · Otsuka America Pharmaceutical, Inc. · $2.84 · Open Payments source 2025-09-10 · Otsuka America Pharmaceutical, Inc. · $51.80 · Open Payments source 2025-09-15 · Lundbeck LLC · $16.31 · Open Payments source 2025-10-01 · Otsuka America Pharmaceutical, Inc. · $7.61 · Open Payments source 2025-10-07 · Otsuka America Pharmaceutical, Inc. · $364.18 · Open Payments source 2025-10-07 · Otsuka America Pharmaceutical, Inc. · $125.00 · Open Payments source 2025-10-07 · Otsuka America Pharmaceutical, Inc. · $364.19 · Open Payments source 2025-10-09 · Otsuka America Pharmaceutical, Inc. · $121.59 · Open Payments source 2025-10-09 · Otsuka America Pharmaceutical, Inc. · $208.43 · Open Payments source 2025-10-09 · Otsuka America Pharmaceutical, Inc. · $22.56 · Open Payments source 2025-10-09 · Otsuka America Pharmaceutical, Inc. · $208.44 · Open Payments source 2025-10-09 · Otsuka America Pharmaceutical, Inc. · $701.13 · Open Payments source 2025-10-09 · Otsuka America Pharmaceutical, Inc. · $276.67 · Open Payments source 2025-10-09 · Otsuka America Pharmaceutical, Inc. · $701.12 · Open Payments source 2025-10-09 · Otsuka America Pharmaceutical, Inc. · $276.66 · Open Payments source 2025-10-10 · Otsuka America Pharmaceutical, Inc. · $467.07 · Open Payments source 2025-10-10 · Otsuka America Pharmaceutical, Inc. · $467.06 · Open Payments source 2025-10-10 · Otsuka America Pharmaceutical, Inc. · $467.07 · Open Payments source 2025-10-10 · Otsuka America Pharmaceutical, Inc. · $19.21 · Open Payments source 2025-10-10 · Otsuka America Pharmaceutical, Inc. · $208.43 · Open Payments source 2025-10-15 · Otsuka America Pharmaceutical, Inc. · $22.41 · Open Payments source 2025-10-15 · Otsuka America Pharmaceutical, Inc. · $3,456.00 · Open Payments source 2025-10-15 · Otsuka America Pharmaceutical, Inc. · $4,104.00 · Open Payments source 2025-10-15 · Otsuka America Pharmaceutical, Inc. · $4,752.00 · Open Payments source 2025-10-15 · Otsuka America Pharmaceutical, Inc. · $3,456.00 · Open Payments source 2025-10-17 · Otsuka America Pharmaceutical, Inc. · $67.83 · Open Payments source 2025-10-17 · Otsuka America Pharmaceutical, Inc. · $67.83 · Open Payments source 2025-10-17 · Otsuka America Pharmaceutical, Inc. · $4,104.00 · Open Payments source 2025-10-17 · Otsuka America Pharmaceutical, Inc. · $67.83 · Open Payments source 2025-10-22 · Otsuka America Pharmaceutical, Inc. · $2,808.00 · Open Payments source 2025-10-23 · Otsuka America Pharmaceutical, Inc. · $143.54 · Open Payments source 2025-10-23 · Otsuka America Pharmaceutical, Inc. · $119.19 · Open Payments source 2025-10-23 · Otsuka America Pharmaceutical, Inc. · $639.15 · Open Payments source 2025-10-28 · Otsuka America Pharmaceutical, Inc. · $106.00 · Open Payments source 2025-10-28 · Otsuka America Pharmaceutical, Inc. · $346.37 · Open Payments source 2025-10-30 · Otsuka America Pharmaceutical, Inc. · $1,613.12 · Open Payments source 2025-10-31 · Otsuka America Pharmaceutical, Inc. · $4,104.00 · Open Payments source 2025-10-31 · Otsuka America Pharmaceutical, Inc. · $23.61 · Open Payments source 2025-10-31 · Otsuka America Pharmaceutical, Inc. · $35.01 · Open Payments source 2025-10-31 · Otsuka America Pharmaceutical, Inc. · $3.99 · Open Payments source 2025-10-31 · Otsuka America Pharmaceutical, Inc. · $4,104.00 · Open Payments source 2025-11-03 · Otsuka America Pharmaceutical, Inc. · $15.66 · Open Payments source 2025-11-05 · Otsuka America Pharmaceutical, Inc. · $65.25 · Open Payments source 2025-11-05 · Otsuka America Pharmaceutical, Inc. · $22.35 · Open Payments source 2025-11-05 · Otsuka America Pharmaceutical, Inc. · $25.00 · Open Payments source 2025-11-05 · Otsuka America Pharmaceutical, Inc. · $3.99 · Open Payments source 2025-11-06 · Otsuka America Pharmaceutical, Inc. · $634.67 · Open Payments source 2025-11-06 · Otsuka America Pharmaceutical, Inc. · $90.47 · Open Payments source 2025-11-06 · Otsuka America Pharmaceutical, Inc. · $122.03 · Open Payments source 2025-11-06 · Otsuka America Pharmaceutical, Inc. · $387.06 · Open Payments source 2025-11-06 · Otsuka America Pharmaceutical, Inc. · $634.69 · Open Payments source 2025-11-06 · Otsuka America Pharmaceutical, Inc. · $90.47 · Open Payments source 2025-11-07 · Otsuka America Pharmaceutical, Inc. · $387.07 · Open Payments source 2025-11-13 · Otsuka America Pharmaceutical, Inc. · $4,752.00 · Open Payments source 2025-11-13 · Otsuka America Pharmaceutical, Inc. · $109.62 · Open Payments source 2025-11-13 · Otsuka America Pharmaceutical, Inc. · $436.97 · Open Payments source 2025-11-15 · Otsuka America Pharmaceutical, Inc. · $804.68 · Open Payments source 2025-11-18 · Otsuka America Pharmaceutical, Inc. · $20.01 · Open Payments source 2025-11-19 · Otsuka America Pharmaceutical, Inc. · $4,104.00 · Open Payments source 2025-11-20 · Lundbeck LLC · $6.56 · Open Payments source 2025-12-03 · Otsuka America Pharmaceutical, Inc. · $4,104.00 · Open Payments source 2025-12-03 · Otsuka America Pharmaceutical, Inc. · $32.62 · Open Payments source 2025-12-03 · Otsuka America Pharmaceutical, Inc. · $4.88 · Open Payments source 2025-12-03 · Otsuka America Pharmaceutical, Inc. · $21.00 · Open Payments source
SPRAVATO Normalized: spravato	Drug	Janssen Pharmaceuticals, Inc	$31,697.64	49	2025
Source payment records 2025-01-13 · Janssen Pharmaceuticals, Inc · $303.96 · Open Payments source 2025-01-14 · Janssen Pharmaceuticals, Inc · $2,940.00 · Open Payments source 2025-01-22 · Janssen Pharmaceuticals, Inc · $18.63 · Open Payments source 2025-02-05 · Janssen Pharmaceuticals, Inc · $550.13 · Open Payments source 2025-02-05 · Janssen Pharmaceuticals, Inc · $143.68 · Open Payments source 2025-02-05 · Janssen Pharmaceuticals, Inc · $469.59 · Open Payments source 2025-02-06 · Janssen Pharmaceuticals, Inc · $9.69 · Open Payments source 2025-02-06 · Janssen Pharmaceuticals, Inc · $20.10 · Open Payments source 2025-02-07 · Janssen Pharmaceuticals, Inc · $14.70 · Open Payments source 2025-02-07 · Janssen Pharmaceuticals, Inc · $9.80 · Open Payments source 2025-02-07 · Janssen Pharmaceuticals, Inc · $50.00 · Open Payments source 2025-02-07 · Janssen Pharmaceuticals, Inc · $13.92 · Open Payments source 2025-02-07 · Janssen Pharmaceuticals, Inc · $33.34 · Open Payments source 2025-02-07 · Janssen Pharmaceuticals, Inc · $120.44 · Open Payments source 2025-02-08 · Janssen Pharmaceuticals, Inc · $13.69 · Open Payments source 2025-02-08 · Janssen Pharmaceuticals, Inc · $97.88 · Open Payments source 2025-02-08 · Janssen Pharmaceuticals, Inc · $12.70 · Open Payments source 2025-02-08 · Janssen Pharmaceuticals, Inc · $56.57 · Open Payments source 2025-02-08 · Janssen Pharmaceuticals, Inc · $35.79 · Open Payments source 2025-02-08 · Janssen Pharmaceuticals, Inc · $15.21 · Open Payments source 2025-02-13 · Janssen Pharmaceuticals, Inc · $124.99 · Open Payments source 2025-02-14 · Janssen Pharmaceuticals, Inc · $8.39 · Open Payments source 2025-02-14 · Janssen Pharmaceuticals, Inc · $28.95 · Open Payments source 2025-03-12 · Janssen Pharmaceuticals, Inc · $7,560.00 · Open Payments source 2025-04-07 · Janssen Pharmaceuticals, Inc · $3,520.00 · Open Payments source 2025-05-12 · Janssen Pharmaceuticals, Inc · $440.00 · Open Payments source 2025-06-17 · Janssen Pharmaceuticals, Inc · $3,520.00 · Open Payments source 2025-06-26 · Janssen Pharmaceuticals, Inc · $113.63 · Open Payments source 2025-06-26 · Janssen Pharmaceuticals, Inc · $21.32 · Open Payments source 2025-06-26 · Janssen Pharmaceuticals, Inc · $124.99 · Open Payments source 2025-06-26 · Janssen Pharmaceuticals, Inc · $18.71 · Open Payments source 2025-06-26 · Janssen Pharmaceuticals, Inc · $20.41 · Open Payments source 2025-06-26 · Janssen Pharmaceuticals, Inc · $16.31 · Open Payments source 2025-07-07 · Janssen Pharmaceuticals, Inc · $3,520.00 · Open Payments source 2025-07-10 · Janssen Pharmaceuticals, Inc · $17.69 · Open Payments source 2025-09-22 · Janssen Pharmaceuticals, Inc · $130.06 · Open Payments source 2025-09-23 · Janssen Pharmaceuticals, Inc · $20.85 · Open Payments source 2025-10-15 · Janssen Pharmaceuticals, Inc · $367.90 · Open Payments source 2025-10-24 · Janssen Pharmaceuticals, Inc · $270.17 · Open Payments source 2025-10-29 · Janssen Pharmaceuticals, Inc · $42.00 · Open Payments source 2025-10-29 · Janssen Pharmaceuticals, Inc · $149.99 · Open Payments source 2025-10-30 · Janssen Pharmaceuticals, Inc · $3,200.00 · Open Payments source 2025-10-31 · Janssen Pharmaceuticals, Inc · $564.03 · Open Payments source 2025-11-19 · Janssen Pharmaceuticals, Inc · $117.73 · Open Payments source 2025-11-19 · Janssen Pharmaceuticals, Inc · $4.88 · Open Payments source 2025-11-19 · Janssen Pharmaceuticals, Inc · $32.62 · Open Payments source 2025-11-19 · Janssen Pharmaceuticals, Inc · $42.28 · Open Payments source 2025-11-19 · Janssen Pharmaceuticals, Inc · $19.92 · Open Payments source 2025-11-21 · Janssen Pharmaceuticals, Inc · $2,750.00 · Open Payments source
AUSTEDO XR Normalized: austedo xr	Drug	Teva Pharmaceuticals USA, Inc.	$11,363.99	22	2025
Source payment records 2025-01-28 · Teva Pharmaceuticals USA, Inc. · $1.36 · Open Payments source 2025-01-28 · Teva Pharmaceuticals USA, Inc. · $7.15 · Open Payments source 2025-03-06 · Teva Pharmaceuticals USA, Inc. · $289.59 · Open Payments source 2025-04-03 · Teva Pharmaceuticals USA, Inc. · $6,081.00 · Open Payments source 2025-06-23 · Teva Pharmaceuticals USA, Inc. · $7.89 · Open Payments source 2025-07-29 · Teva Pharmaceuticals USA, Inc. · $124.99 · Open Payments source 2025-07-29 · Teva Pharmaceuticals USA, Inc. · $2,995.00 · Open Payments source 2025-07-29 · Teva Pharmaceuticals USA, Inc. · $2.12 · Open Payments source 2025-07-30 · Teva Pharmaceuticals USA, Inc. · $4.79 · Open Payments source 2025-08-05 · Teva Pharmaceuticals USA, Inc. · $1,198.00 · Open Payments source 2025-08-07 · Teva Pharmaceuticals USA, Inc. · $1.55 · Open Payments source 2025-08-07 · Teva Pharmaceuticals USA, Inc. · $7.93 · Open Payments source 2025-08-25 · Teva Pharmaceuticals USA, Inc. · $560.00 · Open Payments source 2025-09-03 · Teva Pharmaceuticals USA, Inc. · $1.36 · Open Payments source 2025-09-03 · Teva Pharmaceuticals USA, Inc. · $6.97 · Open Payments source 2025-09-04 · Teva Pharmaceuticals USA, Inc. · $28.93 · Open Payments source 2025-09-09 · Teva Pharmaceuticals USA, Inc. · $1.28 · Open Payments source 2025-09-09 · Teva Pharmaceuticals USA, Inc. · $7.07 · Open Payments source 2025-09-16 · Teva Pharmaceuticals USA, Inc. · $2.17 · Open Payments source 2025-09-16 · Teva Pharmaceuticals USA, Inc. · $12.20 · Open Payments source 2025-11-14 · Teva Pharmaceuticals USA, Inc. · $9.58 · Open Payments source 2025-12-01 · Teva Pharmaceuticals USA, Inc. · $13.06 · Open Payments source
VRAYLAR Normalized: vraylar	Drug	ABBVIE INC.	$5,619.80	17	2025
Source payment records 2025-01-09 · ABBVIE INC. · $3.57 · Open Payments source 2025-05-15 · ABBVIE INC. · $4.94 · Open Payments source 2025-06-05 · ABBVIE INC. · $4.66 · Open Payments source 2025-06-10 · ABBVIE INC. · $17.15 · Open Payments source 2025-06-10 · ABBVIE INC. · $3.78 · Open Payments source 2025-06-23 · ABBVIE INC. · $2,750.00 · Open Payments source 2025-07-01 · ABBVIE INC. · $4.47 · Open Payments source 2025-07-17 · ABBVIE INC. · $5.00 · Open Payments source 2025-08-12 · ABBVIE INC. · $17.06 · Open Payments source 2025-09-11 · ABBVIE INC. · $1.62 · Open Payments source 2025-09-17 · ABBVIE INC. · $5.73 · Open Payments source 2025-09-17 · ABBVIE INC. · $5.21 · Open Payments source 2025-09-25 · ABBVIE INC. · $2,750.00 · Open Payments source 2025-10-10 · ABBVIE INC. · $19.49 · Open Payments source 2025-11-18 · ABBVIE INC. · $7.14 · Open Payments source 2025-12-08 · ABBVIE INC. · $8.19 · Open Payments source 2025-12-15 · ABBVIE INC. · $11.79 · Open Payments source
Auvelity Normalized: auvelity	Drug	Axsome Therapeutics, Inc.	$5,444.33	4	2025
Source payment records 2025-02-12 · Axsome Therapeutics, Inc. · $13.75 · Open Payments source 2025-04-03 · Axsome Therapeutics, Inc. · $5,400.00 · Open Payments source 2025-10-27 · Axsome Therapeutics, Inc. · $10.30 · Open Payments source 2025-11-18 · Axsome Therapeutics, Inc. · $20.28 · Open Payments source
INGREZZA Normalized: ingrezza	Drug	Neurocrine BioSciences, Inc.	$250.50	11	2025
Source payment records 2025-01-07 · Neurocrine BioSciences, Inc. · $19.12 · Open Payments source 2025-01-28 · Neurocrine BioSciences, Inc. · $14.95 · Open Payments source 2025-05-22 · Neurocrine BioSciences, Inc. · $18.34 · Open Payments source 2025-06-11 · Neurocrine BioSciences, Inc. · $22.11 · Open Payments source 2025-06-19 · Neurocrine BioSciences, Inc. · $14.99 · Open Payments source 2025-07-09 · Neurocrine BioSciences, Inc. · $29.98 · Open Payments source 2025-08-20 · Neurocrine BioSciences, Inc. · $26.86 · Open Payments source 2025-09-03 · Neurocrine BioSciences, Inc. · $26.02 · Open Payments source 2025-09-18 · Neurocrine BioSciences, Inc. · $29.01 · Open Payments source 2025-09-30 · Neurocrine BioSciences, Inc. · $24.37 · Open Payments source 2025-10-01 · Neurocrine BioSciences, Inc. · $24.75 · Open Payments source
COBENFY Normalized: cobenfy	Drug	E.R. Squibb & Sons, L.L.C.	$228.07	6	2025
Source payment records 2025-01-23 · E.R. Squibb & Sons, L.L.C. · $124.99 · Open Payments source 2025-02-05 · E.R. Squibb & Sons, L.L.C. · $23.71 · Open Payments source 2025-02-06 · E.R. Squibb & Sons, L.L.C. · $19.37 · Open Payments source 2025-02-11 · E.R. Squibb & Sons, L.L.C. · $22.10 · Open Payments source 2025-08-12 · E.R. Squibb & Sons, L.L.C. · $12.23 · Open Payments source 2025-10-29 · E.R. Squibb & Sons, L.L.C. · $25.67 · Open Payments source
FANAPT Normalized: fanapt	Drug	Vanda Pharmaceuticals Inc.	$136.65	6	2025
Source payment records 2025-07-29 · Vanda Pharmaceuticals Inc. · $17.68 · Open Payments source 2025-08-29 · Vanda Pharmaceuticals Inc. · $25.04 · Open Payments source 2025-09-12 · Vanda Pharmaceuticals Inc. · $13.76 · Open Payments source 2025-09-16 · Vanda Pharmaceuticals Inc. · $24.38 · Open Payments source 2025-11-11 · Vanda Pharmaceuticals Inc. · $25.01 · Open Payments source 2025-12-20 · Vanda Pharmaceuticals Inc. · $30.78 · Open Payments source
LYBALVI Normalized: lybalvi	Drug	Alkermes, Inc.	$131.05	6	2025
Source payment records 2025-01-15 · Alkermes, Inc. · $18.52 · Open Payments source 2025-02-10 · Alkermes, Inc. · $15.09 · Open Payments source 2025-07-15 · Alkermes, Inc. · $22.15 · Open Payments source 2025-07-29 · Alkermes, Inc. · $21.11 · Open Payments source 2025-08-13 · Alkermes, Inc. · $29.43 · Open Payments source 2025-10-20 · Alkermes, Inc. · $24.75 · Open Payments source
ARISTADA Normalized: aristada	Drug	Alkermes, Inc.	$108.90	5	2025
Source payment records 2025-01-15 · Alkermes, Inc. · $18.52 · Open Payments source 2025-02-10 · Alkermes, Inc. · $15.09 · Open Payments source 2025-07-29 · Alkermes, Inc. · $21.11 · Open Payments source 2025-08-13 · Alkermes, Inc. · $29.43 · Open Payments source 2025-10-20 · Alkermes, Inc. · $24.75 · Open Payments source
REJOYN Normalized: rejoyn	Device	Otsuka Pharmaceutical Development & Commercialization, Inc.	$79.40	1	2025
Source payment records 2025-11-11 · Otsuka Pharmaceutical Development & Commercialization, Inc. · $79.40 · Open Payments source
TRINTELLIX Normalized: trintellix	Drug	Takeda Pharmaceuticals U.S.A., Inc.	$71.12	4	2025
Source payment records 2025-01-16 · Takeda Pharmaceuticals U.S.A., Inc. · $17.83 · Open Payments source 2025-02-05 · Takeda Pharmaceuticals U.S.A., Inc. · $18.07 · Open Payments source 2025-05-20 · Takeda Pharmaceuticals U.S.A., Inc. · $19.20 · Open Payments source 2025-06-16 · Takeda Pharmaceuticals U.S.A., Inc. · $16.02 · Open Payments source
UZEDY Normalized: uzedy	Drug	Teva Pharmaceuticals USA, Inc.	$59.83	3	2025
Source payment records 2025-05-21 · Teva Pharmaceuticals USA, Inc. · $17.00 · Open Payments source 2025-05-23 · Teva Pharmaceuticals USA, Inc. · $27.50 · Open Payments source 2025-07-16 · Teva Pharmaceuticals USA, Inc. · $15.33 · Open Payments source
XYWAV Normalized: xywav	Drug	JAZZ PHARMACEUTICALS INC.	$42.95	1	2025
Source payment records 2025-02-07 · JAZZ PHARMACEUTICALS INC. · $42.95 · Open Payments source
Qelbree Normalized: qelbree	Drug	Supernus Pharmaceuticals, Inc.	$30.23	2	2025
Source payment records 2025-08-13 · Supernus Pharmaceuticals, Inc. · $15.08 · Open Payments source 2025-10-15 · Supernus Pharmaceuticals, Inc. · $15.15 · Open Payments source
INVEGA SUSTENNA Normalized: invega sustenna	Drug	Janssen Scientific Affairs, LLC	$27.96	1	2025
Source payment records 2025-08-26 · Janssen Scientific Affairs, LLC · $27.96 · Open Payments source
APLENZIN Normalized: aplenzin	Drug	Bausch Health US, LLC	$21.72	1	2025
Source payment records 2025-08-25 · Bausch Health US, LLC · $21.72 · Open Payments source
WELLBUTRIN Normalized: wellbutrin	Drug	Bausch Health US, LLC	$21.72	1	2025
Source payment records 2025-08-25 · Bausch Health US, LLC · $21.72 · Open Payments source
NURTEC ODT Normalized: nurtec odt	Drug	PFIZER INC.	$21.03	1	2025
Source payment records 2025-09-18 · PFIZER INC. · $21.03 · Open Payments source
ZAVZPRET Normalized: zavzpret	Drug	PFIZER INC.	$21.03	1	2025
Source payment records 2025-09-18 · PFIZER INC. · $21.03 · Open Payments source
VNS THERAPY SYMMETRY MODEL 8103 GENERATOR Normalized: vns therapy symmetry model 8103 generator	Device	LivaNova USA, Inc.	$20.23	1	2025
Source payment records 2025-01-29 · LivaNova USA, Inc. · $20.23 · Open Payments source
ABILIFY ASIMTUFII Normalized: abilify asimtufii	Drug	Otsuka America Pharmaceutical, Inc.	$18.10	1	2025
Source payment records 2025-12-14 · Otsuka America Pharmaceutical, Inc. · $18.10 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
ARISTADA aristada	2025	Aristada	2024	12 Beneficiary count suppressed	exact normalized	Medicare Part D
CAPLYTA caplyta	2025	Caplyta	2024	72	exact normalized	Medicare Part D
FANAPT fanapt	2025	Fanapt	2024	12 Beneficiary count suppressed	exact normalized	Medicare Part D
INVEGA SUSTENNA invega sustenna	2025	Invega Sustenna	2024	30 Beneficiary count suppressed	exact normalized	Medicare Part D
REXULTI rexulti	2025	Rexulti	2024	48	exact normalized	Medicare Part D
TRINTELLIX trintellix	2025	Trintellix	2024	62	exact normalized	Medicare Part D
VRAYLAR vraylar	2025	Vraylar	2024	37	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	VRAYLAR open payments reported associated product	CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550	Vraylar · 2024 Exact normalized brand match · 1 Part D row	37	15
Alkermes, Inc. Exact reporting entity; no affiliate inference	2025	ARISTADA open payments reported associated product	CMS Open Payments — General Payments 76041 supporting records · 17486 recipient NPIs · example record 1222428566	Aristada · 2024 Exact normalized brand match · 1 Part D row	12	suppressed by CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference	2025	CAPLYTA open payments reported associated product	CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071	Caplyta · 2024 Exact normalized brand match · 1 Part D row	72	27
Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference	2025	Caplyta open payments reported associated product	CMS Open Payments — General Payments 11 supporting records · 9 recipient NPIs · example record 1174547314	Caplyta · 2024 Exact normalized brand match · 1 Part D row	72	27
Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference	2025	INVEGA SUSTENNA open payments reported associated product	CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262	Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row	30	suppressed by CMS
Janssen Scientific Affairs, LLC Exact reporting entity; no affiliate inference	2025	INVEGA SUSTENNA open payments reported associated product	CMS Open Payments — General Payments 488 supporting records · 397 recipient NPIs · example record 1174147651	Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row	30	suppressed by CMS
Lundbeck LLC Exact reporting entity; no affiliate inference	2025	ABILIFY MAINTENA open payments reported associated product	CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994	Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row	21	suppressed by CMS
Lundbeck LLC Exact reporting entity; no affiliate inference	2025	REXULTI open payments reported associated product	CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986	Rexulti · 2024 Exact normalized brand match · 1 Part D row	48	19
Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference	2025	ABILIFY MAINTENA open payments reported associated product	CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721	Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row	21	suppressed by CMS
Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference	2025	NUEDEXTA open payments reported associated product	CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901	Nuedexta · 2024 Exact normalized brand match · 1 Part D row	30	suppressed by CMS
Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference	2025	REXULTI open payments reported associated product	CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708	Rexulti · 2024 Exact normalized brand match · 1 Part D row	48	19
Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference	2025	ABILIFY MAINTENA open payments reported associated product	CMS Open Payments — General Payments 87 supporting records · 83 recipient NPIs · example record 1225319985	Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row	21	suppressed by CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference	2025	REXULTI open payments reported associated product	CMS Open Payments — General Payments 1463 supporting records · 1088 recipient NPIs · example record 1225319865	Rexulti · 2024 Exact normalized brand match · 1 Part D row	48	19
Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference	2025	TRINTELLIX open payments reported associated product	CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266	Trintellix · 2024 Exact normalized brand match · 1 Part D row	62	15
Vanda Pharmaceuticals Inc. Exact reporting entity; no affiliate inference	2025	FANAPT open payments reported associated product	CMS Open Payments — General Payments 95605 supporting records · 21383 recipient NPIs · example record 1232940535	Fanapt · 2024 Exact normalized brand match · 1 Part D row	12	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Aripiprazole	Aripiprazole	229	73
Duloxetine Hcl	Duloxetine Hcl	180	46
Lamotrigine	Lamotrigine	122	37
Escitalopram Oxalate	Escitalopram Oxalate	85	20
Quetiapine Fumarate	Quetiapine Fumarate	84	28
Trazodone Hcl	Trazodone Hcl	73	26
Caplyta	Lumateperone Tosylate	72	27
Olanzapine	Olanzapine	69	15
Bupropion Xl	Bupropion Hcl	62	17
Trintellix	Vortioxetine Hydrobromide	62	15
Sertraline Hcl	Sertraline Hcl	61	20
Risperidone	Risperidone	54	17
Buspirone Hcl	Buspirone Hcl	51	14
Paroxetine Hcl	Paroxetine Hcl	50	suppressed
Clonazepam	Clonazepam	48	27
Rexulti	Brexpiprazole	48	19
Fluoxetine Hcl	Fluoxetine Hcl	37	11
Vraylar	Cariprazine Hcl	37	15
Lurasidone Hcl	Lurasidone Hcl	36	suppressed
Gabapentin	Gabapentin	34	14
Venlafaxine Hcl Er	Venlafaxine Hcl	32	suppressed
Invega Sustenna	Paliperidone Palmitate	30	suppressed
Nuedexta	Dextromethorphan Hbr/Quinidine	30	suppressed
Paliperidone Er	Paliperidone	30	suppressed
Citalopram Hbr	Citalopram Hydrobromide	29	suppressed
Mirtazapine	Mirtazapine	25	suppressed
Naltrexone Hcl	Naltrexone Hcl	25	suppressed
Lorazepam	Lorazepam	23	15
Vilazodone Hcl	Vilazodone Hcl	23	suppressed
Lithium Carbonate	Lithium Carbonate	22	suppressed
Abilify Maintena	Aripiprazole	21	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	20	suppressed
Nuplazid	Pimavanserin Tartrate	18	suppressed
Oxcarbazepine	Oxcarbazepine	18	suppressed
Divalproex Sodium	Divalproex Sodium	17	suppressed
Propranolol Hcl	Propranolol Hcl	17	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	16	suppressed
Carbamazepine Er	Carbamazepine	15	suppressed
Divalproex Sodium Er	Divalproex Sodium	15	suppressed
Clozapine	Clozapine	14	suppressed
Haloperidol Decanoate	Haloperidol Decanoate	13	suppressed
Topiramate	Topiramate	13	suppressed
Aristada	Aripiprazole Lauroxil	12	suppressed
Fanapt	Iloperidone	12	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	12	suppressed
Verapamil Hcl	Verapamil Hcl	12	suppressed
Lithium Carbonate Er	Lithium Carbonate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$235,000.19 · 365 records	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	ABILIFY ASIMTUFII, APLENZIN, ARISTADA, AUSTEDO XR, Auvelity, CAPLYTA, COBENFY, FANAPT, INGREZZA, INVEGA SUSTENNA, LYBALVI, NURTEC ODT, Qelbree, REJOYN, REXULTI, SPRAVATO, TRINTELLIX, UZEDY, VNS THERAPY SYMMETRY MODEL 8103 GENERATOR, VRAYLAR, WELLBUTRIN, XYWAV, ZAVZPRET	15	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Aristada play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error